In the context of the 32nd BioCity Symposium (24-25 August 2023) the nineteenth Elias Tillandz prize will be awarded for the best scientific paper published in 2022 in Turku. BioCity…
Dissertation Defence: Deepankar Chakroborty
Comprehensive genetic characterization of cancer tissues was enabled with the advent of next-generation sequencing technologies. These methods helped scientists peer into the cancer genomes, and in the process, improved our…
Turku Bioscience Introduces Robust Approach for Longitudinal Biomarker Discovery in Proteomics Data
New study of Turku Bioscience evaluates tools to detect longitudinal differential expression in proteomics data and introduces a robust approach called RolDE for longitudinal biomarker discovery. Proteins are a large…
University of Turku granted the Title of Docent to Kalle Rytkönen
Dr. Kalle Rytkönen was granted the title of Docent of Physiology and Functional Genomics by the Faculty of Medicine at the University of Turku. His current research focuses on…
Academy of Finland PROFI7 funding to strengthen immunology research at University of Turku
The Academy of Finland has taken decisions on the latest round of PROFI funding, a funding scheme aimed at bolstering the research profiles of Finnish universities. University of Turku was…
Prof. Johanna Ivaska awarded Knight, First Class, of the Order of the White Rose of Finland
We are proud to announce that Johanna Ivaska was awarded Knight, First Class, of the Order of the White Rose of Finland (Suomen Valkoisen Ruusun I luokan ritarimerkki (SVR R…
Research Project on the Development of Human Immune System in Early Life Obtains Multimillion Funding
The first few months and years of life are crucial to the development of the human immune system. This is an important phase as the immune system can define which…
Finnish Diabetes Association PhD thesis award to Essi Laajala
Dr. Essi Laajala was awarded second prize for her PhD thesis in the field of diabetes study by the Finnish Diabetes Association. The award was given at this year’s Diabetes…
Otto Kauko receives Finnish Medical Foundation’s research group founder grant (190 000€)
Responses to targeted cancer therapies are often short-lived, because tumor cells escape the effects of therapy via rewired growth signaling, or due to expansion of small subpopulations of intrinsically drug…
Election of the personnel’s representative to TBC board
The term for Turku Bioscience and BioCity Turku common board is ending this year. One board member is representing TBC people, and it is now time to elect the…